A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Trial details
- Registry ID
- NCT05059223
- Phase
- Phase 3
The PDUFA goal date for AXS-12 (reboxetine) in cataplexy in narcolepsy is 1 May 2027, as disclosed by Axsome Therapeutics, Inc. (AXSM).
Drug identity checked against registry records
Also recorded as AXS-12; reboxetine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyNCT05059223 | AXSM | Phase 3 | Completed | 2024-03-15Actual |
| A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)NCT05113745 | AXSM | Phase 3 | Completed | 2024-11-15Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-05-01Day | AXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSM | Company-disclosed PDUFA goal dateAnnounced review target | cataplexy in narcolepsy | Open original sourceRead source excerptAxsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy FDA sets PDUFA target action date of May 1, 2027 First seen: 25 Sep 2026 · Evidence last checked: 25 Sep 2026 |
| 2027-05-01Day | AXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSM | Company-disclosed PDUFA goal dateAnnounced review target | cataplexy in narcolepsy | Open original sourceRead source excerptAxsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027. First seen: 02 Nov 2026 · Evidence last checked: 02 Nov 2026 |